AI is driving real change, but bubble concerns are growing. Investors must balance exposure to AI with broader opportunities and enduring risks in 2026.
Tune in to hear how Eli Lilly’s groundbreaking GLP-1 therapies could reduce chronic disease and improve longevity worldwide. Eric also explores Eli Lilly’s newly announced partnership with the U.S. government, and Lilly’s commitment to expanding global drug access, scaling manufacturing to meet demand, and harnessing the power of innovation and AI to transform health care.
Nov 2025
MARKET INSIGHTS
May 2025
In the Spotlight
Our insights show you what’s ahead, what’s most important, and how our investment teams are responding now - so you have the full picture.
Hear directly from our experts on timely themes and topics.
202507-4687954